# 64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)

> **NCT04726033** · EARLY_PHASE1 · COMPLETED · sponsor: **Telix Pharmaceuticals (Innovations) Pty Limited** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** 64Cu-DOTA-TLX592

## Key facts

- **NCT ID:** NCT04726033
- **Lead sponsor:** Telix Pharmaceuticals (Innovations) Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-04
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-01-29
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04726033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04726033, "64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04726033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*